First-in-class small molecule inhibitor shows promise against pancreatic cancer in preclinical studies
Mayo Clinic researchers have developed an experimental drug with the help of artificial intelligence (AI) to target the "undruggable" PDZ domain of the GIPC1 protein, which helps different types of cancer, including pancreatic ...
Aug 5, 2026
0
31









